(Q54650178)

English

Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

pharmacokinetics

1 reference

based on heuristic

inferred from title

James Lewis Abbruzzese

4

object named as

James L Abbruzzese

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

8

object named as

Johann de Bono

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

author name string

Lisa A Hammond-Thelin

1

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Melanie B Thomas

2

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Michiko Iwasaki

3

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Yvonne Lassere

5

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Christina A Meyers

6

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Paulo Hoff

7

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Jody Norris

9

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Hitoshi Matsushita

10

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Akira Mita

11

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Eric K Rowinsky

12

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

publication date

14 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

30

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

1

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

316-326

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

https://scigraph.springernature.com/pub.10.1007/s10637-010-9535-y

0 references

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Functional consequences of the arabinosylcytosine structural lesion in DNA.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Mechanistic implications of alterations in HL-60 cell nascent DNA after exposure to 1-beta-D-arabinofuranosylcytosine.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Determination of 3'-C-ethynylcytidine in human plasma and urine by liquid chromatographic-electrospray ionization tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Tailoring the treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Letter: neuropathy due to cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Peripheral neuropathy associated with high-dose Ara-C therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Toxic effects of adriamycin on the ganglia of the peripherial nervous system: a neuropathological study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Damage to the intrinsic cardiac neurones by rubidomycin (daunorubicin).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9535-Y

21 January 2018

Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of a

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor effect of a novel multifunctional antitumor nucleoside, 3'-ethynylcytidine, on human cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cognitive deficits in patients with small cell lung cancer before and after chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of 1-beta-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase beta

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine: preclinical pharmacology and mechanisms of action.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/20839029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9535-Y

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20839029

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54650178&oldid=2144545618"